AbbVie (NYSE:ABBV) Rating Lowered to Buy at Wall Street Zen

AbbVie (NYSE:ABBV) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Sunday.

Other research analysts have also issued research reports about the stock. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Citigroup decreased their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Stock Down 0.4%

Shares of ABBV opened at $226.72 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market capitalization of $400.69 billion, a price-to-earnings ratio of 107.96, a PEG ratio of 1.42 and a beta of 0.50. The stock has a fifty day moving average of $227.71 and a 200-day moving average of $206.80.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.

Institutional Trading of AbbVie

A number of institutional investors have recently bought and sold shares of ABBV. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. SPC Financial Inc. acquired a new stake in AbbVie in the first quarter worth $254,000. OVERSEA CHINESE BANKING Corp Ltd increased its stake in AbbVie by 53.3% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 5,687 shares of the company’s stock valued at $1,192,000 after purchasing an additional 1,978 shares in the last quarter. Finally, R Squared Ltd increased its stake in AbbVie by 1,485.7% in the first quarter. R Squared Ltd now owns 1,110 shares of the company’s stock valued at $233,000 after purchasing an additional 1,040 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.